- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00577330
Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis
December 19, 2007 updated by: ProThera, Inc.
The Efficacy of Myalgesin™ for the Support of Joint Function in Patients With Osteoarthritis of the Knee - A Prospective Randomized Controlled Study
Myalgesin is a botanical preparation consisting of celery seed extract,extract of dried Boswellia serrata, and dried extract of Phellodendron bark.
Component of these extracts have been shown to exert anti-inflammatory effects and to inhibit cyclooxygenase and 5-lipooxygenase.
The study is based on the hypothesis that oral administrration of this botanical will support joint function in people with osteoarthritis of the knee and improve symptoms and mobility as measured by the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index.
Study Overview
Status
Unknown
Conditions
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Albany, New York, United States, 12203
- Stuart I. Erner, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women age 50-years or older.
- Patients with symptomatic osteoarthritis of the knees as defined by the American College of Rheumatology criteria(traditional format).
- At least moderate pain in the knee (rated at 40 or greater by the subject on a visual analogue scale) for most days during the last month.
- Use of analgesic or anti-inflammatory agents for control of pain for at least 1 month.
- Baseline functional capacity class 1 to 3, in which class 1 is complete ability to carry out usual activities without handicap,class 2 is ability to adequately conduct usual activities despite handicap of discomfort or limited mobility of one or more joints,and class 3 is limited ability to carry out usual activities. (American Rheumatism Association functional class)
- Documented radiographic changes of osteoarthritis on a previous knee radiograph (Kellgren-Lawrence grade of 2 or more).
Exclusion Criteria:
- Age <50-years.
- Body mass index (BMI) equal to or greater than 35 kg/m2.
- Baseline functional class 4 with the subject bedridden or confined to wheelchair, largely or wholly incapacitated and capable of little or no self-care. (American Rheumatism Association functional class)
- Inflammatory arthritis, gout, pseudogout, or Paget's disease.
- Presence of chronic pain syndromes, such as fibromyalgia or reflex sympathetic dystrophy, that may interfere with the assessment of joint symptomatology.
- Severe bursitis of the knee.
- History of acute joint trauma within 30 days of study entry.
- Complete loss of articular cartilage.
- History of total knee replacement.
- Intra-articular/intramuscular corticosteroids within 30 days of study entry.
- Intra-articular hyaluronan and hyalans within 30 days of study entry.
- History of gastrointestinal bleeding within 1 year of study entry.
- Active peptic ulcer disease, gastroesophageal reflux disease, or inflammatory bowel disease.
- Gastrointestinal tract ulceration within 30 days of study entry.
- Severe renal dysfunction defined as a serum creatinine greater than 2 mg/dL.
- Clinically significant liver disease including an aspartate aminotransferase or alanine aminotransferase >2 times the upper limit of normal.
- Unwillingness or inability to abstain from ethanol for the study duration.
- Significant bleeding disorder.
- History of gastric or duodenal surgery.
- Warfarin use.
- Sensitivity to acetaminophen or to any of the components of Myalgesin™.
- Pregnancy.
- Any serious medical, social or psychological condition that, in the opinion of the Principal Investigator, would disqualify a subject from participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Myalgesin
Subjects receive Myalgesin twice daily
|
Twice daily
|
ACTIVE_COMPARATOR: Acetaminophen
Subjects receive acetaminophen 1000 mg three times a day
|
Twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index
Time Frame: 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lesquesne Algofunctional Index
Time Frame: 90 days
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Stuart I Erner, MD, Private Practice
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Study Completion (ANTICIPATED)
January 1, 2008
Study Registration Dates
First Submitted
December 18, 2007
First Submitted That Met QC Criteria
December 18, 2007
First Posted (ESTIMATE)
December 20, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
December 28, 2007
Last Update Submitted That Met QC Criteria
December 19, 2007
Last Verified
December 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MYG-01-2006
- 20052687
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)
-
Egyptian Biomedical Research NetworkCompleted
-
Ali AltunkayaNational Cancer Institute (NCI)TerminatedBrain and Central Nervous System Tumors | Cerebral EdemaUnited States
-
University of Alabama at BirminghamCongressionally Directed Medical Research ProgramsCompleted